Bosentan improved syncope in a hemodialysis patient with pulmonary hypertension and mild aortic stenosis.
Pulmonary arterial hypertension (PAH), caused by collagen diseases, Eisenmenger syndrome or of idiopathic etiology, generally has a poor prognosis. Recently, bosentan, a dual endothelin receptor antagonist, has become available for treating PAH. This report describes a bosentan-effective case of combined PAH, hemodialysis and mild aortic stenosis. A 71-year-old woman on hemodialysis was referred to our hospital because of repetitive syncope. Although neurological examinations revealed no etiological diseases, echocardiography and cardiac catheterization showed PAH and mild aortic valve stenosis. Bosentan abolished syncope with improvement of hemodynamic parameters. This report suggests bosentan was clinically useful in a hemodialysis patient with pulmonary hypertension and mild aortic valve stenosis.
Yamanaka
Asuka
A
Second Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka, Japan.
Tasaki
Hiromi
H
Suzuki
Yoshiyuki
Y
Tanaka
Seiya
S
Yamashita
Kazuhito
K
Tamura
Masahito
M
Abe
Haruhiko
H
Otsuji
Yutaka
Y
D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001024:Aortic Valve Stenosis / Q000150:complications*; D000077300:Bosentan; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications* / Q000188:drug therapy; D006435:Renal Dialysis; D013449:Sulfonamides / Q000627:therapeutic use*; D013575:Syncope / Q000188:drug therapy*
D000959:Antihypertensive Agents; D013449:Sulfonamides; D000077300:Bosentan